Otenabant

• CAT Number: I004580
• CAS Number: 686344-29-6
• Molecular Formula: C25H25Cl2N7O
• Molecular Weight: 510.42
• Purity: ≥95%
• Synonyms: 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-(ethylamino)piperidine-4-carboxamide
• Target: Neuronal Signaling
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 0.7 nM(Ki for binding)/0.2 nM (Ki for function) [1]
• InChI: InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)
• InChIKey: UNAZAADNBYXMIV-UHFFFAOYSA-N
• SMILES: CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N

Otenabant（Cat No.:I004580）is an experimental drug that acts as a selective inverse agonist of the cannabinoid receptor CB1. CB1 receptors are involved in regulating appetite, mood, and metabolic processes, and their activation has been linked to conditions like obesity and metabolic disorders. Otenabant was developed to target these receptors and potentially treat obesity by reducing appetite and promoting weight loss. In clinical trials, the drug demonstrated efficacy in reducing body weight, but its development was discontinued due to concerns over psychiatric side effects, including depression and anxiety. Further research into CB1 receptor modulators continues.

Reference

[1]. John R. Hadcock, David A. Griffith, Dennis O. Scott In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity. Biochemical and Biophysical Research Communications,2010; 394;366-371.
[2]. Zhuang Miao, Dennis O. Scott, David A. Griffith. Excretion, Metabolism, and Pharmacokinetics of CP-945,598, a Selective Cannabinoid Receptor Antagonist, in Rats, Mice, and Dogs. Drug Metab. Dispos. 2011; 39: 568-578.
[3]. Griffith DA, Hadcock JR, Black SC, Discovery of 1-[9-(4-chlorophenyl) -8-(2-chlorophenyl)- 9H-purin-6-yl] -4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. JMedChem. 2009 ;52(2):234-7.